coramitug
·Code: PRX004
coramitug: developed by 1 company · 1 clinical trial tracked.
coramitug evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect coramitug to PRTA; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could coramitug → PRTA affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
ATTR-CM
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| PROTHENA CORP PUBLIC LTD CO (PRTA) ATTR-CM | Phase 3 |
Clinical Trials (1)
An Open-label Study to Evaluate the Biodistribution of 89Zr-coramitug and Investigate the Effects of Coramitug on Depleting TTR Amyloid Deposits in Myocardial Tissues Using PET/CT Imaging in Participants With ATTR-CM
Primary endpoint: Mean Standard Uptake Value Ratio (SUVRmean) in myocardium
Interventionalopen14 targetStarted 2026-03Completion 2028-071 site · NetherlandsNovo Nordisk A/S
Frequently asked questions
Who is developing coramitug?
coramitug is being developed by PROTHENA CORP PUBLIC LTD CO.
How many clinical trials involve coramitug?
BioSniper tracks 1 clinical trial involving coramitug.